Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease
Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease
Study to assess the long-term safety and effectiveness of Spiolto in Japanese patients with
 Chronic Obstructive Pulmonary Disease (COPD) in real-world setting
Inclusion criteria:

 -  Patients who have been diagnosed with chronic obstructive pulmonary disease (chronic
 bronchitis, emphysema) by physician and need relief of various symptoms associated
 with Long Acting Beta2 Agonist (LABA) or Long Acting Muscarinic Antagonist (LAMA).

 -  Patients who are prescribed Tio+Olo FDC 5µg/5µg for the first time

 Exclusion criteria:

 -  Patients who have been registered once in this study (i.e., re-entry of patients is
 not allowed).

 -  Patients who are participating in a registry or clinical trial.

 -  Patients who have a contraindication to Tio+Olo FDC 5µg/5µg defined in the package
 insert for Tio+Olo FDC 5µg/5µg.